Clinical Trial

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

Name: BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases — clinical trial record (NCT06794008)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The objective of this study is to evaluate the efficacy and safety of BCMA/CD19 chimeric antigen receptor (CAR)-modified T cells in the treatment of autoimmune diseases.

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2025-01-20; most recent amendment 2025-04-01.

Trial Details

NCT Number	NCT06794008
Lead Sponsor	Peking University People's Hospital
Conditions	Systemic Lupus Erythematosus, Inflammatory Myopathy, Systemic Sclerosis (SSc), ANCA-associated Vasculitis, IgG4-Related Diseases, Antiphospholipid Syndrome, Acquired Thrombotic Thrombocytopenic Purpura, Behcet Disease +1 more
Enrollment	50 participants
Start Date	2024-12-26
Primary Completion	2027-12-30 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-04-02